Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 1999 March;47(3) > Minerva Cardioangiologica 1999 March;47(3):55-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

ORIGINAL ARTICLES  


Minerva Cardioangiologica 1999 March;47(3):55-8

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: English, Italian

Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy

Trifiletti A., Bartolone S., Scamardi R., Pizzoleo M. A., Attinà A., Sottilotta G., Canobbio V., Soraci S., Barbera N.


PDF  


Background. In this study the action of a prostaglandin, PGE1, was studied in a group of patients with peripheral arterial occlusive disease (PAOD).
Methods. In 16 patients (14 men and 2 women, aged 47-70 years, mean 57±7) with PAOD, Fontaine stage IIb and III in critical ischemia, the effects on two indexes of thrombin generation and action of the endovenous administration (2 hours) of 60 mg of Alprostadil-PGE1 for four weeks were evaluated. In all artheriopathic patients, before and after pharmacological treatment, the following haemostatic parameters were evaluated: the prothrombin fragment 1+2 (F1+2) and the fibrinopeptide A(FPA).
Results. The patients showed plasma levels of FPA significantly decreased at the end of the treatment. On the other hand, no significant difference in plasma F1+2 levels was observed after treatment.
Conclusions. These results seem to indicate that plasma F1+2 levels are significantly elevated, as a marker of thrombosis status, in patients with PAOD before and after treatment with PGE1.

top of page

Publication History

Cite this article as

Corresponding author e-mail